Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

p19-Targeting ILP Protein Blockers of IL-23/Th-17 Pro-Inflammatory Axis Displayed on Engineered Bacteria of Food Origin

K. Škrlec, P. Zadravec, M. Hlavničková, M. Kuchař, L. Vaňková, H. Petroková, L. Křížová, J. Černý, A. Berlec, P. Malý,

. 2018 ; 19 (7) : . [pub] 20180701

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19000596

Grantová podpora
NV16-27676A MZ0 CEP - Centrální evidence projektů

IL-23-mediated Th-17 cell activation and stimulation of IL-17-driven pro-inflammatory axis has been associated with autoimmunity disorders such as Inflammatory Bowel Disease (IBD) or Crohn’s Disease (CD). Recently we developed a unique class of IL-23-specific protein blockers, called ILP binding proteins that inhibit binding of IL-23 to its cognate cell-surface receptor (IL-23R) and exhibit immunosuppressive effect on human primary blood leukocytes ex vivo. In this study, we aimed to generate a recombinant Lactococcus lactis strain which could serve as in vivo producer/secretor of IL-23 protein blockers into the gut. To achieve this goal, we introduced ILP030, ILP317 and ILP323 cDNA sequences into expression plasmid vector containing USP45 secretion signal, FLAG sequence consensus and LysM-containing cA surface anchor (AcmA) ensuring cell-surface peptidoglycan anchoring. We demonstrate that all ILP variants are expressed in L. lactis cells, efficiently transported and secreted from the cell and displayed on the bacterial surface. The binding function of AcmA-immobilized ILP proteins is documented by interaction with a recombinant p19 protein, alpha subunit of human IL-23, which was assembled in the form of a fusion with Thioredoxin A. ILP317 variant exhibits the best binding to the human IL-23 cytokine, as demonstrated for particular L.lactis-ILP recombinant variants by Enzyme-Linked ImmunoSorbent Assay (ELISA). We conclude that novel recombinant ILP-secreting L. lactis strains were developed that might be useful for further in vivo studies of IL-23-mediated inflammation on animal model of experimentally-induced colitis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19000596
003      
CZ-PrNML
005      
20190107104409.0
007      
ta
008      
190107s2018 sz f 000 0|eng||
024    7_
$a 10.3390/ijms19071933 $2 doi
035    __
$a (PubMed)29966384
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Škrlec, Katja $u Department of Biotechnology, Jožef Stefan Institute, Jamova 39, SI-1000 Ljubljana, Slovenia. katja.skrlec@ijs.si. Graduate School of Biomedicine, Faculty of Medicine, University of Ljubljana, SI-1000 Ljubljana, Slovenia. katja.skrlec@ijs.si.
245    10
$a p19-Targeting ILP Protein Blockers of IL-23/Th-17 Pro-Inflammatory Axis Displayed on Engineered Bacteria of Food Origin / $c K. Škrlec, P. Zadravec, M. Hlavničková, M. Kuchař, L. Vaňková, H. Petroková, L. Křížová, J. Černý, A. Berlec, P. Malý,
520    9_
$a IL-23-mediated Th-17 cell activation and stimulation of IL-17-driven pro-inflammatory axis has been associated with autoimmunity disorders such as Inflammatory Bowel Disease (IBD) or Crohn’s Disease (CD). Recently we developed a unique class of IL-23-specific protein blockers, called ILP binding proteins that inhibit binding of IL-23 to its cognate cell-surface receptor (IL-23R) and exhibit immunosuppressive effect on human primary blood leukocytes ex vivo. In this study, we aimed to generate a recombinant Lactococcus lactis strain which could serve as in vivo producer/secretor of IL-23 protein blockers into the gut. To achieve this goal, we introduced ILP030, ILP317 and ILP323 cDNA sequences into expression plasmid vector containing USP45 secretion signal, FLAG sequence consensus and LysM-containing cA surface anchor (AcmA) ensuring cell-surface peptidoglycan anchoring. We demonstrate that all ILP variants are expressed in L. lactis cells, efficiently transported and secreted from the cell and displayed on the bacterial surface. The binding function of AcmA-immobilized ILP proteins is documented by interaction with a recombinant p19 protein, alpha subunit of human IL-23, which was assembled in the form of a fusion with Thioredoxin A. ILP317 variant exhibits the best binding to the human IL-23 cytokine, as demonstrated for particular L.lactis-ILP recombinant variants by Enzyme-Linked ImmunoSorbent Assay (ELISA). We conclude that novel recombinant ILP-secreting L. lactis strains were developed that might be useful for further in vivo studies of IL-23-mediated inflammation on animal model of experimentally-induced colitis.
650    _2
$a ELISA $7 D004797
650    _2
$a průtoková cytometrie $7 D005434
650    _2
$a lidé $7 D006801
650    _2
$a interleukin-23 $x metabolismus $7 D053759
650    _2
$a Lactococcus lactis $x metabolismus $7 D013294
650    _2
$a vazba proteinů $7 D011485
650    _2
$a proteiny $x genetika $x metabolismus $x farmakologie $7 D011506
650    _2
$a rekombinantní proteiny $x genetika $x metabolismus $x farmakologie $7 D011994
650    _2
$a buňky Th17 $x účinky léků $7 D058504
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zadravec, Petra $u Department of Biotechnology, Jožef Stefan Institute, Jamova 39, SI-1000 Ljubljana, Slovenia. petrazadravec@gmail.com.
700    1_
$a Hlavničková, Marie $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, v. v. i., BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic. marie.hlavnickova@ibt.cas.cz.
700    1_
$a Kuchař, Milan $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, v. v. i., BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic. milan.kuchar@ibt.cas.cz.
700    1_
$a Vaňková, Lucie $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, v. v. i., BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic. lucie.vankova@ibt.cas.cz.
700    1_
$a Petroková, Hana $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, v. v. i., BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic. hana.petrokova@ibt.cas.cz.
700    1_
$a Křížová, Lucie $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, v. v. i., BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic. lucie.krizova@ibt.cas.cz.
700    1_
$a Černý, Jiří $u Laboratory of Structural Bioinformatics of Proteins, Institute of Biotechnology of the Czech Academy of Sciences, v. v. i., BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic. jiri.cerny@ibt.cas.cz.
700    1_
$a Berlec, Aleš $u Department of Biotechnology, Jožef Stefan Institute, Jamova 39, SI-1000 Ljubljana, Slovenia. ales.berlec@ijs.si. Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, SI-1000 Ljubljana, Slovenia. ales.berlec@ijs.si.
700    1_
$a Malý, Petr $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, v. v. i., BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic. petr.maly@ibt.cas.cz.
773    0_
$w MED00176142 $t Int J Mol Sci $x 1422-0067 $g Roč. 19, č. 7 (2018), s.
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29966384 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a
990    __
$a 20190107 $b ABA008
999    __
$a ok $b bmc $g 1364648 $s 1038719
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 19 $c 7 $e 20180701 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a NV16-27676A $p MZ0
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...